Jump Financial LLC Makes New $452,000 Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Jump Financial LLC acquired a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLAFree Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 14,295 shares of the company’s stock, valued at approximately $452,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in Intellia Therapeutics by 7.3% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,651 shares of the company’s stock worth $210,000 after purchasing an additional 451 shares in the last quarter. Victory Capital Management Inc. boosted its position in Intellia Therapeutics by 1.8% during the third quarter. Victory Capital Management Inc. now owns 27,316 shares of the company’s stock worth $864,000 after purchasing an additional 470 shares in the last quarter. Principal Financial Group Inc. boosted its position in Intellia Therapeutics by 16.8% during the third quarter. Principal Financial Group Inc. now owns 23,965 shares of the company’s stock worth $758,000 after purchasing an additional 3,440 shares in the last quarter. Teacher Retirement System of Texas boosted its position in Intellia Therapeutics by 4.8% during the third quarter. Teacher Retirement System of Texas now owns 22,531 shares of the company’s stock worth $712,000 after purchasing an additional 1,039 shares in the last quarter. Finally, Resonant Capital Advisors LLC purchased a new stake in Intellia Therapeutics during the third quarter worth $989,000. Institutional investors and hedge funds own 87.72% of the company’s stock.

Intellia Therapeutics Trading Up 2.8 %

Intellia Therapeutics stock opened at $28.23 on Friday. The firm has a market capitalization of $2.53 billion, a P/E ratio of -5.28 and a beta of 1.74. The stock has a fifty day moving average price of $28.39 and a 200 day moving average price of $31.31. Intellia Therapeutics, Inc. has a 52 week low of $22.67 and a 52 week high of $47.48.

Intellia Therapeutics (NASDAQ:NTLAGet Free Report) last released its earnings results on Thursday, November 9th. The company reported ($1.38) EPS for the quarter, beating the consensus estimate of ($1.52) by $0.14. The firm had revenue of $11.99 million during the quarter, compared to analyst estimates of $12.45 million. Intellia Therapeutics had a negative return on equity of 40.49% and a negative net margin of 893.34%. The business’s quarterly revenue was down 9.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.49) earnings per share. As a group, equities analysts predict that Intellia Therapeutics, Inc. will post -5.42 EPS for the current year.

Insiders Place Their Bets

In other Intellia Therapeutics news, EVP David Lebwohl sold 5,843 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $29.46, for a total transaction of $172,134.78. Following the completion of the sale, the executive vice president now directly owns 54,372 shares in the company, valued at $1,601,799.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Intellia Therapeutics news, EVP Laura Sepp-Lorenzino sold 2,275 shares of the company’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $28.87, for a total transaction of $65,679.25. Following the completion of the sale, the executive vice president now directly owns 43,927 shares in the company, valued at $1,268,172.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David Lebwohl sold 5,843 shares of the stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $29.46, for a total value of $172,134.78. Following the completion of the sale, the executive vice president now owns 54,372 shares of the company’s stock, valued at approximately $1,601,799.12. The disclosure for this sale can be found here. Insiders sold 32,706 shares of company stock worth $962,177 over the last three months. 3.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have commented on NTLA shares. Royal Bank of Canada decreased their target price on Intellia Therapeutics from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Friday, November 10th. Wedbush reiterated a “neutral” rating and set a $45.00 target price on shares of Intellia Therapeutics in a research report on Thursday, November 2nd. BMO Capital Markets reduced their price objective on Intellia Therapeutics from $64.00 to $62.00 and set an “outperform” rating on the stock in a research report on Friday, November 10th. Oppenheimer reduced their price objective on Intellia Therapeutics from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Monday, November 13th. Finally, Raymond James reduced their price objective on Intellia Therapeutics from $78.00 to $57.00 and set an “outperform” rating on the stock in a research report on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $75.00.

Check Out Our Latest Stock Report on Intellia Therapeutics

About Intellia Therapeutics

(Free Report)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas.

Featured Stories

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLAFree Report).

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.